| Product Code: ETC13245143 | Publication Date: Apr 2025 | Updated Date: Jul 2025 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | Author: Bhawna Singh | No. of Pages: 190 | No. of Figures: 80 | No. of Tables: 40 |
According to 6Wresearch internal database and industry insights, the Global Age-Related Macular Degeneration Market was valued at USD 11.6 Billion in 2024 and is expected to reach USD 17.3 Billion by 2031, growing at a compound annual growth rate of 17.27% during the forecast period (2025-2031).
The Global Age-Related Macular Degeneration (AMD) Market is experiencing growth driven by factors such as an aging population, increasing prevalence of AMD, advancements in diagnostic technologies, and rising awareness about eye health. The market is characterized by the presence of key players offering innovative treatments, including anti-VEGF drugs, supplements, and surgical interventions. Geographically, North America and Europe hold significant market shares due to well-established healthcare infrastructure and high adoption rates of advanced therapies. However, the Asia-Pacific region is expected to witness the fastest growth due to improving healthcare facilities, rising disposable incomes, and a growing geriatric population. Key trends in the market include personalized medicine approaches, telemedicine solutions, and ongoing research and development efforts to discover more effective treatments for AMD.
The Global Age-Related Macular Degeneration (AMD) market is experiencing a shift towards innovative treatments such as gene therapy, stem cell therapy, and personalized medicine. The increasing elderly population, rising prevalence of AMD, and advancements in diagnostic technologies are driving market growth. Opportunities lie in the development of novel therapies targeting different stages of AMD, as well as the expansion of treatment options in emerging markets. Collaboration between pharmaceutical companies and research institutions for clinical trials and research projects is also on the rise. Additionally, the adoption of telemedicine and artificial intelligence in AMD diagnosis and management presents new avenues for market expansion. Overall, the AMD market is evolving rapidly, offering significant potential for growth and innovation in the coming years.
The Global Age-Related Macular Degeneration (AMD) market faces several challenges, including the high cost of treatment options, limited access to healthcare services in certain regions, and the increasing prevalence of AMD due to aging populations worldwide. Additionally, there is a need for more effective and targeted therapies for AMD, as current treatment options are not always successful in halting disease progression. The market also experiences challenges related to regulatory hurdles, such as lengthy approval processes for new drugs and treatments. Furthermore, the competitive landscape of the AMD market is intense, with multiple pharmaceutical companies vying for market share, leading to pricing pressures and the need for innovative strategies to differentiate products and reach patients effectively. Overall, addressing these challenges will be crucial for the continued growth and advancement of the Global AMD market.
The Global Age-Related Macular Degeneration (AMD) market is primarily driven by the increasing prevalence of AMD among the aging population, with the elderly being more susceptible to this condition. Technological advancements in diagnostic tools and treatment options, such as anti-VEGF drugs and gene therapy, are also driving market growth by improving patient outcomes and expanding the range of available treatment choices. Additionally, rising awareness about the importance of early detection and treatment of AMD, along with the growing demand for innovative therapies, are contributing to market expansion. Moreover, the increasing focus of pharmaceutical companies on developing novel drugs and therapies for AMD is expected to further propel market growth in the coming years.
Government policies related to the Global Age-Related Macular Degeneration (AMD) Market primarily focus on promoting research and development initiatives, increasing access to AMD treatment options, and implementing measures to reduce the burden of AMD on healthcare systems. These policies often include funding support for AMD-related research projects, regulatory guidelines to ensure the safety and efficacy of AMD treatments, and reimbursement mechanisms to make AMD therapies more affordable for patients. Additionally, some countries may have specific programs to raise awareness about AMD and its risk factors, as well as initiatives to improve early diagnosis and management of the disease. Overall, government policies in the AMD market aim to address the growing prevalence of AMD, improve patient outcomes, and enhance the sustainability of healthcare systems in the face of an aging population.
The Global Age-Related Macular Degeneration (AMD) market is expected to witness steady growth in the coming years, driven by factors such as an aging population, increasing prevalence of AMD, advancements in diagnostic technologies, and the introduction of innovative treatment options. The market is likely to see a rise in research and development activities aimed at developing more effective therapies, including gene therapies and regenerative medicine approaches. Additionally, the growing awareness about eye health and the availability of government initiatives to improve access to AMD treatment are expected to further propel market growth. However, challenges such as high treatment costs and limited reimbursement coverage in some regions may hinder market expansion to a certain extent. Overall, the Global AMD market is poised for growth, with opportunities for companies to cater to the evolving needs of patients and healthcare providers.
In the global Age-Related Macular Degeneration (AMD) market, Asia is projected to witness significant growth due to the increasing aging population and rising prevalence of AMD in countries like Japan and China. North America is expected to dominate the market due to advanced healthcare infrastructure, high awareness about AMD, and the presence of key market players. Europe follows closely behind, driven by the growing adoption of advanced treatment options for AMD. The Middle East and Africa region is anticipated to show steady growth, supported by improving healthcare facilities and rising awareness about eye diseases. Latin America is also expected to witness growth due to increasing healthcare expenditure and the rising prevalence of AMD in countries like Brazil and Mexico. Overall, the global AMD market presents opportunities for growth across all regions, with varying degrees of market maturity and potential.
Global Age-Related Macular Degeneration Market |
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Global Age-Related Macular Degeneration Market Overview |
3.1 Global Regional Macro Economic Indicators |
3.2 Global Age-Related Macular Degeneration Market Revenues & Volume, 2021 & 2031F |
3.3 Global Age-Related Macular Degeneration Market - Industry Life Cycle |
3.4 Global Age-Related Macular Degeneration Market - Porter's Five Forces |
3.5 Global Age-Related Macular Degeneration Market Revenues & Volume Share, By Regions, 2021 & 2031F |
3.6 Global Age-Related Macular Degeneration Market Revenues & Volume Share, By Product, 2021 & 2031F |
3.7 Global Age-Related Macular Degeneration Market Revenues & Volume Share, By Disease Type, 2021 & 2031F |
3.8 Global Age-Related Macular Degeneration Market Revenues & Volume Share, By Distribution Channel, 2021 & 2031F |
4 Global Age-Related Macular Degeneration Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.3 Market Restraints |
5 Global Age-Related Macular Degeneration Market Trends |
6 Global Age-Related Macular Degeneration Market, 2021 - 2031 |
6.1 Global Age-Related Macular Degeneration Market, Revenues & Volume, By Product, 2021 - 2031 |
6.1.1 Overview & Analysis |
6.1.2 Global Age-Related Macular Degeneration Market, Revenues & Volume, By Eylea, 2021 - 2031 |
6.1.3 Global Age-Related Macular Degeneration Market, Revenues & Volume, By Lucentis, 2021 - 2031 |
6.1.4 Global Age-Related Macular Degeneration Market, Revenues & Volume, By Beovu, 2021 - 2031 |
6.1.5 Global Age-Related Macular Degeneration Market, Revenues & Volume, By Others, 2021 - 2031 |
6.2 Global Age-Related Macular Degeneration Market, Revenues & Volume, By Disease Type, 2021 - 2031 |
6.2.1 Overview & Analysis |
6.2.2 Global Age-Related Macular Degeneration Market, Revenues & Volume, By Dry AMD, 2021 - 2031 |
6.2.3 Global Age-Related Macular Degeneration Market, Revenues & Volume, By Wet AMD, 2021 - 2031 |
6.3 Global Age-Related Macular Degeneration Market, Revenues & Volume, By Distribution Channel, 2021 - 2031 |
6.3.1 Overview & Analysis |
6.3.2 Global Age-Related Macular Degeneration Market, Revenues & Volume, By Hospital Pharmacy, 2021 - 2031 |
6.3.3 Global Age-Related Macular Degeneration Market, Revenues & Volume, By Specialty Pharmacy, 2021 - 2031 |
6.3.4 Global Age-Related Macular Degeneration Market, Revenues & Volume, By Online Pharmacy, 2021 - 2031 |
7 North America Age-Related Macular Degeneration Market, Overview & Analysis |
7.1 North America Age-Related Macular Degeneration Market Revenues & Volume, 2021 - 2031 |
7.2 North America Age-Related Macular Degeneration Market, Revenues & Volume, By Countries, 2021 - 2031 |
7.2.1 United States (US) Age-Related Macular Degeneration Market, Revenues & Volume, 2021 - 2031 |
7.2.2 Canada Age-Related Macular Degeneration Market, Revenues & Volume, 2021 - 2031 |
7.2.3 Rest of North America Age-Related Macular Degeneration Market, Revenues & Volume, 2021 - 2031 |
7.3 North America Age-Related Macular Degeneration Market, Revenues & Volume, By Product, 2021 - 2031 |
7.4 North America Age-Related Macular Degeneration Market, Revenues & Volume, By Disease Type, 2021 - 2031 |
7.5 North America Age-Related Macular Degeneration Market, Revenues & Volume, By Distribution Channel, 2021 - 2031 |
8 Latin America (LATAM) Age-Related Macular Degeneration Market, Overview & Analysis |
8.1 Latin America (LATAM) Age-Related Macular Degeneration Market Revenues & Volume, 2021 - 2031 |
8.2 Latin America (LATAM) Age-Related Macular Degeneration Market, Revenues & Volume, By Countries, 2021 - 2031 |
8.2.1 Brazil Age-Related Macular Degeneration Market, Revenues & Volume, 2021 - 2031 |
8.2.2 Mexico Age-Related Macular Degeneration Market, Revenues & Volume, 2021 - 2031 |
8.2.3 Argentina Age-Related Macular Degeneration Market, Revenues & Volume, 2021 - 2031 |
8.2.4 Rest of LATAM Age-Related Macular Degeneration Market, Revenues & Volume, 2021 - 2031 |
8.3 Latin America (LATAM) Age-Related Macular Degeneration Market, Revenues & Volume, By Product, 2021 - 2031 |
8.4 Latin America (LATAM) Age-Related Macular Degeneration Market, Revenues & Volume, By Disease Type, 2021 - 2031 |
8.5 Latin America (LATAM) Age-Related Macular Degeneration Market, Revenues & Volume, By Distribution Channel, 2021 - 2031 |
9 Asia Age-Related Macular Degeneration Market, Overview & Analysis |
9.1 Asia Age-Related Macular Degeneration Market Revenues & Volume, 2021 - 2031 |
9.2 Asia Age-Related Macular Degeneration Market, Revenues & Volume, By Countries, 2021 - 2031 |
9.2.1 India Age-Related Macular Degeneration Market, Revenues & Volume, 2021 - 2031 |
9.2.2 China Age-Related Macular Degeneration Market, Revenues & Volume, 2021 - 2031 |
9.2.3 Japan Age-Related Macular Degeneration Market, Revenues & Volume, 2021 - 2031 |
9.2.4 Rest of Asia Age-Related Macular Degeneration Market, Revenues & Volume, 2021 - 2031 |
9.3 Asia Age-Related Macular Degeneration Market, Revenues & Volume, By Product, 2021 - 2031 |
9.4 Asia Age-Related Macular Degeneration Market, Revenues & Volume, By Disease Type, 2021 - 2031 |
9.5 Asia Age-Related Macular Degeneration Market, Revenues & Volume, By Distribution Channel, 2021 - 2031 |
10 Africa Age-Related Macular Degeneration Market, Overview & Analysis |
10.1 Africa Age-Related Macular Degeneration Market Revenues & Volume, 2021 - 2031 |
10.2 Africa Age-Related Macular Degeneration Market, Revenues & Volume, By Countries, 2021 - 2031 |
10.2.1 South Africa Age-Related Macular Degeneration Market, Revenues & Volume, 2021 - 2031 |
10.2.2 Egypt Age-Related Macular Degeneration Market, Revenues & Volume, 2021 - 2031 |
10.2.3 Nigeria Age-Related Macular Degeneration Market, Revenues & Volume, 2021 - 2031 |
10.2.4 Rest of Africa Age-Related Macular Degeneration Market, Revenues & Volume, 2021 - 2031 |
10.3 Africa Age-Related Macular Degeneration Market, Revenues & Volume, By Product, 2021 - 2031 |
10.4 Africa Age-Related Macular Degeneration Market, Revenues & Volume, By Disease Type, 2021 - 2031 |
10.5 Africa Age-Related Macular Degeneration Market, Revenues & Volume, By Distribution Channel, 2021 - 2031 |
11 Europe Age-Related Macular Degeneration Market, Overview & Analysis |
11.1 Europe Age-Related Macular Degeneration Market Revenues & Volume, 2021 - 2031 |
11.2 Europe Age-Related Macular Degeneration Market, Revenues & Volume, By Countries, 2021 - 2031 |
11.2.1 United Kingdom Age-Related Macular Degeneration Market, Revenues & Volume, 2021 - 2031 |
11.2.2 Germany Age-Related Macular Degeneration Market, Revenues & Volume, 2021 - 2031 |
11.2.3 France Age-Related Macular Degeneration Market, Revenues & Volume, 2021 - 2031 |
11.2.4 Rest of Europe Age-Related Macular Degeneration Market, Revenues & Volume, 2021 - 2031 |
11.3 Europe Age-Related Macular Degeneration Market, Revenues & Volume, By Product, 2021 - 2031 |
11.4 Europe Age-Related Macular Degeneration Market, Revenues & Volume, By Disease Type, 2021 - 2031 |
11.5 Europe Age-Related Macular Degeneration Market, Revenues & Volume, By Distribution Channel, 2021 - 2031 |
12 Middle East Age-Related Macular Degeneration Market, Overview & Analysis |
12.1 Middle East Age-Related Macular Degeneration Market Revenues & Volume, 2021 - 2031 |
12.2 Middle East Age-Related Macular Degeneration Market, Revenues & Volume, By Countries, 2021 - 2031 |
12.2.1 Saudi Arabia Age-Related Macular Degeneration Market, Revenues & Volume, 2021 - 2031 |
12.2.2 UAE Age-Related Macular Degeneration Market, Revenues & Volume, 2021 - 2031 |
12.2.3 Turkey Age-Related Macular Degeneration Market, Revenues & Volume, 2021 - 2031 |
12.3 Middle East Age-Related Macular Degeneration Market, Revenues & Volume, By Product, 2021 - 2031 |
12.4 Middle East Age-Related Macular Degeneration Market, Revenues & Volume, By Disease Type, 2021 - 2031 |
12.5 Middle East Age-Related Macular Degeneration Market, Revenues & Volume, By Distribution Channel, 2021 - 2031 |
13 Global Age-Related Macular Degeneration Market Key Performance Indicators |
14 Global Age-Related Macular Degeneration Market - Export/Import By Countries Assessment |
15 Global Age-Related Macular Degeneration Market - Opportunity Assessment |
15.1 Global Age-Related Macular Degeneration Market Opportunity Assessment, By Countries, 2021 & 2031F |
15.2 Global Age-Related Macular Degeneration Market Opportunity Assessment, By Product, 2021 & 2031F |
15.3 Global Age-Related Macular Degeneration Market Opportunity Assessment, By Disease Type, 2021 & 2031F |
15.4 Global Age-Related Macular Degeneration Market Opportunity Assessment, By Distribution Channel, 2021 & 2031F |
16 Global Age-Related Macular Degeneration Market - Competitive Landscape |
16.1 Global Age-Related Macular Degeneration Market Revenue Share, By Companies, 2024 |
16.2 Global Age-Related Macular Degeneration Market Competitive Benchmarking, By Operating and Technical Parameters |
17 Top 10 Company Profiles |
18 Recommendations |
19 Disclaimer |
Export potential enables firms to identify high-growth global markets with greater confidence by combining advanced trade intelligence with a structured quantitative methodology. The framework analyzes emerging demand trends and country-level import patterns while integrating macroeconomic and trade datasets such as GDP and population forecasts, bilateral import–export flows, tariff structures, elasticity differentials between developed and developing economies, geographic distance, and import demand projections. Using weighted trade values from 2020–2024 as the base period to project country-to-country export potential for 2030, these inputs are operationalized through calculated drivers such as gravity model parameters, tariff impact factors, and projected GDP per-capita growth. Through an analysis of hidden potentials, demand hotspots, and market conditions that are most favorable to success, this method enables firms to focus on target countries, maximize returns, and global expansion with data, backed by accuracy.
By factoring in the projected importer demand gap that is currently unmet and could be potential opportunity, it identifies the potential for the Exporter (Country) among 190 countries, against the general trade analysis, which identifies the biggest importer or exporter.
To discover high-growth global markets and optimize your business strategy:
Click Here